Procyon Advisors LLC Purchases 63 Shares of Zoetis Inc. (NYSE:ZTS)

Procyon Advisors LLC lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 1.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,712 shares of the company’s stock after acquiring an additional 63 shares during the period. Procyon Advisors LLC’s holdings in Zoetis were worth $768,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Pensionfund Sabic increased its holdings in shares of Zoetis by 55.6% in the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after purchasing an additional 4,000 shares in the last quarter. PFW Advisors LLC bought a new stake in Zoetis in the 4th quarter worth about $1,764,000. JPMorgan Chase & Co. raised its position in Zoetis by 10.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock worth $569,834,000 after buying an additional 279,092 shares during the last quarter. Simplify Asset Management Inc. purchased a new position in Zoetis in the 3rd quarter worth about $11,684,000. Finally, B&L Asset Management LLC bought a new position in Zoetis during the 3rd quarter valued at about $563,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ZTS has been the subject of several research reports. Stifel Nicolaus decreased their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Leerink Partners began coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. JPMorgan Chase & Co. lifted their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Finally, UBS Group assumed coverage on Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $211.89.

Zoetis Trading Down 2.0 %

Zoetis stock opened at $166.01 on Friday. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53. The firm has a market capitalization of $74.90 billion, a price-to-earnings ratio of 31.20, a P/E/G ratio of 2.51 and a beta of 0.89. The firm has a 50 day moving average of $170.93 and a 200 day moving average of $179.95. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same period in the prior year, the company posted $1.36 earnings per share. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. As a group, research analysts predict that Zoetis Inc. will post 5.91 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be paid a $0.50 dividend. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.20%. Zoetis’s dividend payout ratio is 32.52%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.